Khronicheskie zabolevaniya pecheni -ot patogeneza k lecheniyu
- Authors: Oskanova R.S1, Il'chenko L.Y.1, Fedorov I.G1
-
Affiliations:
- Issue: No 14 (2013)
- Pages: 62-65
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282332
- ID: 282332
Cite item
Open Access
Access granted
Abstract
Chronic diseases of hepar are extremely widespread and appear to be the great problem for healthcare. The aspects and capabilities of drug correction of chronic hepatic disorders are discussed in this article; etiological factors and pathogenesis specifics are taken into consideration as well. Despite etiotropic treatment directed to the main cause of disease elimination, authors pay their great attention to the pathogenic therapy. They emphasize that the main condition of efficacy for drugs with potential hepatoprotective activity is their ability to influence the hepatic cells membranes lipid peroxidation, to stabilize membranes and to show anti-inflammatory activity.
Full Text
References
- Ивашкин В.Т. Болезни печени и желчевыводящих путей: Руководство для врачей М., 2002. 416 с
- Losser MR, Payen D. Mechanisms of liver damage. Seminar in liver disease 1996;16:357-67.
- Яковенко Э.П., Григорьев П.Я. Хронические заболевания печени: диагностика и лечение // Человек и лекарство 2006. № 5. С. 291-96.
- Kuntz E, Kuntz H-D. Hepatology, Principles and practice: history, morphology, biochemistry, diagnostics, clinic, therapy. Berlin Heidelberg New York Springer - Verlag, 2000:825.
- Машковский М.Д. Лекарственные средства: В 2 т. 14-е изд., перераб., испр. и доп. М., 2000. 540 с.
- Мубаракшина О.А. Гепатопротекторы: сравнительная характеристика и аспекты клинического использования // Медицинский вестник 2008. № 34.
- Ткач С.М. Эффективность и безопасность гепатопротекторов с точки зрения доказательной медицины // Здоровье Украины 2009. № 6. С. 7-10.
- Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis 2007;39:293-304.
- Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.)Integr Cancer Ther 2007;6:146-57.
- Loguercio С ,Festi D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 2011;17(18):2288-301.
- Fu H, Katsumura Y, Lin M, Hata K, Muroya Y, Hatano Y. Fast repair activities towards dGMP hydroxyl radical adducts by silybin and its analogues. J Radiat Res (Tokyo) 2008; 49:609-14.
- Ligeret H, Brault A, Vallerand D, Haddad Y, Haddad PS. Antioxidant and mitochondrial protective effects of silibinin in cold preservationwarm reperfusion liver injury. J Ethnopharmacol 2007;115(3):507-14.
- Loguercio С, Festi D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 2011;17(18):2288-301.
- Gazak R, Walterov D, Kren V. Silybin and silyma rin--new and emerging applications in medicine. Curr Med Chem 2007;14:315-38.
- Detaille D, Sanchez C, Sanz N, et al. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci 2008;82:1070-76.
- Guigas B, Naboulsi R, Villanueva GR, et al. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perfused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase. Cell Physiol Biochem 2007;20: 925-34.
- Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase 3/7 activity. Drug Metab Dispos 2008;36(9):1909-16.
Supplementary files
